Progestin Tx reasonably effective for early endometrial cancer

July 3, 2013
Progestin tx reasonably effective for early endometrial cancer
Conservative management with oral progestin can be a reasonable treatment option for many patients with stage 1A endometrial cancer, according to research published in the July issue of Obstetrics & Gynecology.

(HealthDay)—Conservative management with oral progestin can be a reasonable treatment option for many patients with stage 1A endometrial cancer, according to research published in the July issue of Obstetrics & Gynecology.

Jeong-Yeol Park, M.D., Ph.D., from the University of Ulsan in Korea, and colleagues reviewed the medical records of 48 women (age 40 years or younger) with endometrioid adenocarcinoma of the uterus who were treated conservatively with oral .

The researchers found that 14 (29.2 percent) received daily oral megestrol acetate (median dose, 160 mg per day) and 34 patients (70.8 percent) received daily oral medroxyprogesterone acetate (median dose, 500 mg per day). After the median treatment duration of 10 months, 37 patients (77.1 percent) had complete responses. For patients with stage IA, grade 2 to 3 without myometrial invasion (17 patients), complete response was 76.5 percent; for patients with stage IA, grade 1 with superficial myometrial invasion (23), complete response was 73.9 percent; and for patients with stage IA, grade 2 to 3 with superficial myometrial invasion (eight), complete response was 87.5 percent). After a median follow-up time of 48 months, recurrence rates for 37 patients who had achieved a complete response were 23.1, 47.1, and 71.4 percent, respectively. No disease progression or death from the disease occurred. Nine patients gave birth to 10 healthy newborns.

"Progestin treatment appears to be reasonably effective for patients with stage IA, grade 2 to 3 differentiation without myometrial invasion and patients with stage IA grade 1 differentiation with superficial myometrial invasion," the authors write.

Explore further: Chemo combination promising for multiple myeloma

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Chemo combination promising for multiple myeloma

May 2, 2012

(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according ...

ASCO: Dabrafenib/Trametinib active in metastatic melanoma

May 17, 2012

(HealthDay) -- For patients with V600 BRAF-mutant solid tumors, treatment with the oral BRAF inhibitor dabrafenib and the oral MEK 1/2 inhibitor trametinib is tolerated and has clinical activity in BRAF inhibitor-naive metastatic ...

Prognostic factors identified in mucoepidermoid carcinoma

August 10, 2012

(HealthDay) -- Diagnosis of low- or intermediate-grade tumors is associated with significantly better overall survival and disease-free survival in patients with mucoepidermoid carcinoma (MEC) of the salivary glands, while ...

Low-risk bladder cancer rarely progresses to muscle invasion

March 6, 2013

(HealthDay)—Low-risk bladder cancer rarely progresses to muscle invasion but is associated with an increased risk of disease-specific mortality compared with matched populations, according to research published in the March ...

Recommended for you

Does mom's cellphone startle the fetus?

May 6, 2015

(HealthDay)—The sounds emitted by cellphones carried by pregnant women may rattle the sleep-and-wake cycles of their fetuses, new research suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.